Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4370373 | 0.80 | GAA (0.50) | GAAKDM4EPKMTDP1MAPK1 | |
| SCHEMBL4370382 | 0.80 | SMN1; SMN2 (0.55) | GAATDP1KMT2APOLBHTT | |
| SCHEMBL4300275 | 0.77 | CYP1A2 (0.41) | GAAKDM4EMAPK1KMT2AHTT | |
| SCHEMBL14229436 | 0.76 | GAA (0.54) | GAAKDM4ETDP1MAPK1KMT2A | |
| SCHEMBL23412892 | 0.74 | GAA (0.55) | GAAKDM4ETDP1POLBCYP2C19 | |
| SCHEMBL11001118 | 0.74 | HTT (0.50) | GAAKDM4EPKMTDP1MAPK1 | |
| SCHEMBL11353314 | 0.74 | RAD52 (0.59) | GAAKDM4EPKMMAPK1KMT2A | |
| SCHEMBL7110800 | 0.73 | KMT2A (0.58) | GAAKDM4ETDP1MAPK1KMT2A | |
| SCHEMBL10792107 | 0.73 | MAPT (0.49) | GAAKDM4EPKMTDP1MAPK1 | |
| SCHEMBL7104656 | 0.72 | TDP1 (0.50) | GAAKDM4ETDP1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390343-B1 | NOVEL RETINOID DERIVATIVES AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO LTD (KR) | 2009-10-14 | — | — | EP | disclosed |
| US-7166744-B2 | Retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | CHEBIGEN CO., LTD. (KR) | 2007-01-23 | — | — | US | disclosed |
| EP-1390343-A4 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO LTD (KR) | 2005-06-22 | — | — | EP | disclosed |
| EP-1390343-A1 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | Chebigen Co., Ltd. (KR) | 2004-02-25 | — | — | EP | disclosed |
| US-20030171339-A1 | Novel retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | CHEBIGEN CO., LTD. (KR) | 2003-09-11 | — | — | US | disclosed |
| WO-2002096857-A1 | NOVEL RETINOID DERIVATIVES AND METHODS FOR PRODUCING SAID COMPOUNDS AND AN ANTI-CANCER PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOUNDS | CHEBIGEN CO., LTD. (KR) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171339-A1 | Novel retinoid derivatives and methods for producing said compounds and anti-cancer pharmaceutical composition comprising said compounds | RXRB, RARB, RXRA | GAA 4262/4885KDM4E 2832/4885PKM 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.